NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill

Source Summary

NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovascular risk beyond LDL-C. Key catalysts into 2026–27; valuation execution risk.